Sunshine Coast University Private Hospital | Clinical Trials

Research site

(Unclaimed)

Location

3 Doherty street, Birtinya, Queensland, Australia

Site insights

Top conditions

Top treatments

Sacituzumab

Etrasimod

LM-108

ARC101

ARV-471

HLX301

BL0020

Nivolumab

IBI343

Trastuzumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 17 total trials

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

This is a Phase 1a/b, multicenter, open-label, first-in-human, dose escalation, expansion and extension study to evaluate the safety, tolerability, a...

Enrolling

Locally Advanced Unresectable or Metastatic Solid Tumors

Drug: IBI343

Locations recently updated

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician...

Enrolling

Metastatic HER2-positive Breast Cancer

Drug: Trastuzumab

Drug: Gemcitabine

A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

For phase I ,this study is to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D) and/or Maximum Tolerated Dose (MTD) for...

Not yet enrolling

Advanced Solid Tumours

Drug: LM-168

Drug: Toripalimab

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127)

The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not...

Active, not recruiting

Melanoma

Drug: Nivolumab + Relatlimab

Drug: rHuPH20

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer (VERITAC-2)

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Active, not recruiting

Advanced Breast Cancer

Drug: ARV-471

Drug: Fulvestrant

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis (ELEVATE UC OLE)

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely...

Active, not recruiting

Ulcerative Colitis

Drug: Etrasimod

ARC101 in Advanced Solid Tumors

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ARC101 in patients with advanced cancer.

Enrolling

Advanced Solid Tumor

Drug: ARC101

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

The purpose of this study is to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with...

Enrolling

Hormone-receptor-positive Breast Cancer

Metastatic Breast Cancer

Drug: Fulvestrant

Drug: BGB-21447

HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors

This Phase 1/2, multicenter, first-in-human, open-label, dose-escalation, dose expansion, and clinical expansion study will evaluate the safety, tole...

Enrolling

Locally Advanced or Metastatic Solid Tumors

Non-small Cell Lung Cancer

Drug: HLX301

Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors

This is the first in human study of BL0020, and the primary objective is to evaluate the safety and tolerability, and determine the maximum tolerated...

Enrolling

Advanced Solid Tumor

Drug: BL0020

Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours

This is a first-in-human, Phase I/II, open-label, multi-centre, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokin...

Enrolling

Advanced Solid Tumor

Drug: An Anti-PD-1 Antibody

Drug: LM-108

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (EVOKE-01)

The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or meta...

Active, not recruiting

Non-Small Cell Lung Cancer

Biological: Sacituzumab Govitecan-hziy (SG)

Drug: Docetaxel

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) (EVOKE-02)

The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizu...

Active, not recruiting

Non-small Cell Lung Cancer

Drug: Sacituzumab Govitecan-hziy (SG)

Drug: Pembrolizumab

This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy with Envafolimab in Patients with Advanced or Metastatic Solid Tumors.

This is an open label, two-part, multicenter, multi-regional phase I trial to investigate the safety, tolerability, and PK of KGX101 monotherapy and...

Active, not recruiting

Advanced or Metastatic Solid Tumors

Drug: KGX101 and Envafolimab

Drug: KGX101- Cohort 2